Cholic acid-based novel micellar nanoplatform for delivering FDA-approved taxanes.

Content Provider	Europe PMC
Author	Bharadwaj, Gaurav Nhan, Viet Yang, ShanChao Li, Xiaocen Narayanan, Anand Macarenco, Ana Carolina Shi, Yu Yang, Darrion Vieira, Letícia Salvador Xiao, Wenwu Li, Yuanpei Lam, Kit S
Copyright Year	2017
Abstract	Aim: To structurally modify our existing cholic acid (CA)-based telodendrimer (TD; PEG5K-CA8) for effective micellar nanoencapsulation and delivery of the US FDA-approved members of taxane family. Materials & methods: Generation of hybrid TDs was achieved by replacing four of the eight CAs with biocompatible organic moieties using solution-phase peptide synthesis. Drug loading was done using the standard evaporation method. Results: Hybrid TDs can generate micelles with narrow size distributions, low critical micelle concentration values (1–6 μM), better hematocompatibility and lack of in vitro cytotoxicity. Conclusion: Along with PEG5K-CA8, CA-based hybrid nanoplatform is the first of its kind that can stably encapsulate all three FDA-approved taxanes with nearly 100% efficiency up to 20% (w/w) loading.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC5480805&blobtype=pdf
ISSN	17435889
Volume Number	12
DOI	10.2217/nnm-2017-0361
PubMed Central reference number	PMC5480805
Issue Number	10
PubMed reference number	28447909
Journal	Nanomedicine [Nanomedicine (Lond)]
e-ISSN	17486963
Language	English
Publisher	Future Medicine Ltd
Publisher Date	2017-04-27
Publisher Place	London, UK
Access Restriction	Open
Rights License	© 2017 Future Medicine Ltd
Subject Keyword	cabazitaxel cholic acid docetaxel drug delivery micelle nanoparticle paclitaxel taxane telodendrimer
Content Type	Text
Resource Type	Article
Subject	Nanoscience and Nanotechnology Medicine Development Bioengineering Materials Science Biomedical Engineering